Aardvark Therapeutics (AARD) Cash from Investing Activities (2024 - 2026)
Aardvark Therapeutics (AARD) posted Cash from Investing Activities of $34.2 million for Q1 2026, up 40.93% sequentially from $24.3 million in Q4 2025, and up 130.41% YoY from $14.9 million in Q1 2025.
Aardvark Therapeutics (AARD) Cash from Investing Activities (2024 - 2026) Analysis & Trends
Aardvark Therapeutics has reported Cash from Investing Activities for 3 years, with the latest figure at $34.2 million in Q1 2026.
- Quarterly Cash from Investing Activities rose 130.41% year-over-year to $34.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $97.2 million (up 178.0% YoY) and the FY2025 annual result came in at -$49.7 million, down 313.96% from the prior year.
- Cash from Investing Activities advanced to $34.2 million in Q1 2026 per AARD's latest filing, from $24.3 million in the prior quarter.
- Over five years, Cash from Investing Activities peaked at $34.2 million in Q1 2026 and troughed at -$112.6 million in Q1 2025.
- A 3-year average of -$3.0 million and a median of -$5000.0 in 2024 frame the typical range for Cash from Investing Activities.
- The widest YoY moves for Cash from Investing Activities: up 585020.0% in 2025, down 2252380.0% in 2025.
- Over 3 years, Cash from Investing Activities stood at -$11.9 million in 2024, then jumped by 304.3% to $24.3 million in 2025, then soared by 40.93% to $34.2 million in 2026.
- According to Business Quant data, Cash from Investing Activities over the past three periods registered $34.2 million, $24.3 million, and $29.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | Aardvark Therapeutics | 147.46 Mn | 73.54 Mn | - | 28.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 28.75 Mn |
| Jun 30, 2026 | 28.75 Mn |
| Mar 31, 2026 | 34.25 Mn |
| Mar 31, 2026 | 34.25 Mn |
| Dec 31, 2025 | 24.30 Mn |
| Dec 31, 2025 | 24.30 Mn |
| Sep 30, 2025 | 29.25 Mn |
| Sep 30, 2025 | 29.25 Mn |
| Jun 30, 2025 | 9.41 Mn |
| Jun 30, 2025 | 9.41 Mn |
| Mar 31, 2025 | -112.62 Mn |
| Mar 31, 2025 | -112.62 Mn |
| Dec 31, 2024 | -11.90 Mn |
| Dec 31, 2024 | -11.90 Mn |
| Sep 30, 2024 | -5,000.00 |
| Sep 30, 2024 | -5,000.00 |
| Jun 30, 2024 | -93,000.00 |
| Jun 30, 2024 | -93,000.00 |
| Mar 31, 2024 | -5,000.00 |
| Mar 31, 2024 | -5,000.00 |